Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has reported its first quarter financial results for the period ending March 31, ...

Investing.com -- Moody’s Ratings has uplifted the rating of Royalty Pharma plc’s senior unsecured notes from Baa3 to Baa2. The outlook for the company has also been revised, shifting from positive to ...

The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ.

Drugmakers breathed a sigh of relief Wednesday after President Trump didn’t announce pharmaceutical tariffs. Plus, language in the executive order indicated medicines were exempted from the ...